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Abstract 
Anthramycin (ANT) was the first pyrrolobenzodiazepine (PBD) molecule to be 
isolated, and is a potent cytotoxic agent. Although the PBD family has been investigated for 
use in systemic chemotherapy, their application in the management of actinic keratoses (AK) 
or skin cancer has not been investigated to date. In the present work, anthramycin (ANT) was 
selected as a model PBD compound, and the skin penetration of the molecule was 
investigated using conventional Franz diffusion cells. Finite dose permeation studies of ANT 
were performed using propylene glycol (PG), 1,3-butanediol (BD), dipropylene glycol 
(DiPG), Transcutol P® (TC), propylene glycol monocaprylate (PGMC), propylene glycol 
monolaurate (PGML) and isopropyl myristate (IPM). The skin penetration of BD, DiPG, PG 
and TC was also measured. Penetration of ANT through human skin was evident for TC, PG 
and PGML with the active appearing to “track” the permeation of the vehicle in the case of 
TC and PG. Deposition of ANT in skin could be correlated with skin retention of the vehicle 
in the case of IPM, PGMC and PGML. These preliminary findings confirm the ability of 
ANT to penetrate human skin and, given the potency of the molecule, suggest that further 
investigation is justified. Additionally, the findings emphasise the critical importance of 
understanding the fate of the excipient for the rational design of topical formulations.   
Keywords 
Skin cancer, anthramycin, pyrrolobenzodiazepines, PBDs, solvents, permeation, Franz 
diffusion cell, topical therapy 
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1. Introduction 
Because of their relative lack of pigmentation Caucasian populations are at a much 
higher risk of suffering from non-melanoma and melanoma skin cancers than darker skinned 
ethnic groups (Diepgen and Mahler, 2002).  Today, skin cancer is also the most common 
cancer in individuals with lighter skin tones (Byrd-Miles et al., 2007). The disruption of 
deoxyribonucleic acid (DNA) in skin cells by ultraviolet (UV) radiation is the initial step in 
development of skin cancer. Subsequently, DNA repair mechanisms are not activated and the 
neoplasm progresses. Initially the cancer develops in the outer skin layers and may progress 
and metastasise to deeper locations in the tissues. It has been proposed that the appearance of 
actinic keratoses (AKs) or solar keratoses on the skin is the earliest sign of skin cancer 
(Ibrahim and Brown, 2009). AKs are usually scaly or crusty growths and develop because of 
chronic skin damage associated with sun exposure. Treatment options for skin cancer include 
surgery, systemic or topical chemotherapy, radiation, photodynamic light therapy, 
immunotherapy and targeted therapy. Topical chemotherapy has been used in the 
management of AKs and non-melanoma skin cancers rather than melanoma, because of the 
aggressive nature of the latter (Erickson and Miller, 2010). The advantage of topical delivery 
is that most of the drug is delivered to the site of the lesion and thus there are far fewer side-
effects compared with oral or intravenous administration. To date, there are very few agents 
used for topical chemotherapy, and these include 5-flurouracil, imiquimod, diclofenac 
sodium, ingenol mebutate and alitretinoin (Haque et al., 2015).   
Pyrrolobenzodiazepines (PBDs) are sequence-selective minor groove DNA-interacting 
antitumour agents. Anthramycin (ANT) was the first compound of the pyrrolobenzodiazepine 
(PBD) group to be identified. It was obtained from a natural source, namely a thermophilic 
actinomycete (Streptomyces refuineus) in 1963 (Tendler and Korman, 1963). A fermentation 
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broth containing ANT was found to inhibit sarcoma 180 and adenocarcinoma 755 tumours to 
a significant extent (Leimgruber et al., 1965a; Tendler and Korman, 1963). The active 
compound was isolated by Berger and co-workers, and the structure determined to be 
5,10,11,11a-tetrahydro-9,11-di-hydroxy-8-methyl-5-oxo-1H-pyrrolo[2,1-
c][1,4]benzodiazepine-2acrylamide (see Table 2). The generic name ‘anthramycin’ was 
proposed based on its structural similarity to anthranilic acid (Leimgruber et al., 1965a; 
Leimgruber et al., 1965b). ANT (the N10-C11 carbinolamine form) may also be isolated as 
the equivalent anthramycin N10-C11 methyl ether or as anhydroanthramycin depending on 
the solvent used to dissolve or crystallise the compound. However, the biological activities of 
the three forms of ANT are equivalent as once dissolved in aqueous media (e.g., biological 
fluids) the carbinolamine form is predominant (Adamson et al., 1968; Leimgruber et al., 
1965a; Leimgruber et al., 1965b).  In animal models, ANT exhibited significant positive 
antitumour activity when given subcutaneously once daily (0.10 mg/kg/d) for a total of 8 
doses against human epidermoid carcinoma (H. Ep. No. 3) in conditioned weanling rats 
(Grunberg et al., 1966). ANT inhibits RNA and DNA synthesis, with preferred binding to 
double-stranded DNA rather than single stranded DNA (Kohn et al., 1968). The 
carbinolamine form of ANT was found to be the reactive group that predominantly binds to 
DNA. However, ANT causes very little disruption of the DNA double-helix  (Hurley and 
Petrusek, 1979; Petrusek et al., 1981). The ANT-DNA adduct prevents further nucleic acid 
synthesis and therefore, cell division.  
Zbinden and co-workers showed that ANT exhibited dose-dependent cardiotoxicity 
(Cargill et al., 1974). Therefore, despite its potent cytotoxic properties and antitumour effects, 
it was not developed further as an anticancer drug. More recently, members of the PBD 
family have been developed as cytotoxic payloads for attachment to antibodies to form 
Antibody-Drug Conjugates (ADCs), and a number of these are presently in the clinic for the 
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treatment of various leukaemias and lung cancer (Mantaj et al., 2017).  However, the 
administration of ANT, other than via the systemic route, has not been investigated to date. 
Therefore, the aims of the present work were (i) to investigate the suitability of ANT for 
topical delivery, and (ii) to identify suitable vehicles for targeting of ANT to the skin. If 
effective amounts of ANT penetrate the skin, the potential to progress the molecule as a 
topical chemotherapeutic agent may be explored further. As reported previously, vehicle 
selection was based on an assessment of solubility parameter values of various solvents and 
solubility determination (Parisi et al., 2016).  
 
2. Materials and methods 
2.1 Materials 
ANT was purchased from Sigma Aldrich, UK. Propylene glycol (PG), isopropyl 
myristate (IPM) and acetone were supplied by Sigma Aldrich, UK. Transcutol
®
 (TC), 
Capryol 90® or propylene glycol monocaprylate (PGMC) Type II and Lauroglycol 90® or 
propylene glycol monolaurate (PGML) Type II were obtained from Gattefossé, France. 
Dipropylene glycol (DiPG) and n-octanol (99% pure) obtained from Acros Organics (UK). 
1,3-butanediol (BD) was purchased from Wako Pure Chemical Industries Ltd., Japan. High 
Performance Liquid Chromatography (HPLC) grade water, methanol, acetonitrile, and 
trifluoroacetic acid (TFA) were purchased from Fisher Scientific, UK. For gas 
chromatography (GC) analysis, 1,2-butanediol (>98% pure, internal standard for PG) and 
phenylboronic acid (≥97% pure, a derivatising agent for both PG and BD) were supplied by 
Fluka (Sigma Aldrich, Japan) and Fluka (Sigma Aldrich, UK), respectively. To prepare the 
receptor medium, phosphate-buffered saline (PBS) tablets (Dulbecco A, Oxoid Limited, UK), 
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deionised water (Elga water purifier, UK) and sodium azide (Fluka, Sigma Aldrich, UK) 
were used. 
 
2.2 Log P, solubility parameter calculation, solubility and stability   
The Log P value for ANT was determined experimentally using the shake flask 
method with n-octanol and water (United States Environmental Protection Agency, 1996); 
Log P values for the  solvents were calculated using ChemBioDraw® Ultra (Version 12.0) 
software (PerkinElmer, USA). Solubility parameters for ANT and vehicles were calculated 
using Molecular Modelling Pro® (Version 6.3.3) software (ChemSW, Fairfield, CA, USA). 
Solubility studies were conducted by adding a large excess of ANT into a fixed 
volume of solvent in an Eppendorf® tube. The tubes were capped and sealed with Parafilm®. 
The tubes were shaken for 10 min using a vortex shaker (IKA
®
 Vortex Genius 3, UK). A 
rotor (Stuart, UK) was placed inside a temperature-controlled oven (Jouan, France). The oven 
temperature was set at 32±0.5
°
C. The Eppendorf® tube was placed in the rotor, rotating at 40 
rpm and left for 48 h. At the end of the study, the tube was centrifuged at 13,000 rpm, at 32
°
C 
and for 20 min (Centrifuge 5415R, Eppendorf, Germany). The supernatant portion was 
collected and diluted sufficiently for HPLC analysis. The experiments were conducted in 
triplicate. 
The stability studies were conducted by dissolving known quantities of ANT in neat 
solvents (n=3). The vials were shaken for 5 min to ensure mixing of the compounds in the 
solvent and then filtered using a Millex® GP filter unit (0.22 μm, Millipore Express®, 
Ireland). The solution was placed in a glass vial, capped and sealed using Parafilm® and 
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placed in a water bath at 32±0.5
°
C. Samples were collected at 0, 24 and 48 h, diluted if 
necessary, and analysed by HPLC as described in the next section.   
 
2.3 HPLC analysis 
A Hewlett Packard series 1050 HPLC machine (USA) with a variable wavelength 
UV-VIS detector was used to analyse ANT, with  a Waters Sunfire (UK) C18 column (250× 
4.6 mm, 5 µm packing particle size). Data were collected at a detection wavelength of 240 
nm using Prime® (Version 4.2.0) software. The mobile phase consisted of water (0.1% 
TFA):methanol (50:50). The flow rate of the mobile phase was 1 ml/min and the injection 
volume was 20 μl. Under these conditions the retention time of ANT was 6.4 min. Standard 
solutions of ANT in methanol were prepared in the range of 1.1 to 88 μg/ml. A good 
correlation (r
2
>0.99) was observed between the concentration and the respective peak area, 
with an accuracy value of 100.97±3.56%. The relative standard deviation (%RSD) values of 
intra- and inter-day precision were ≤3.1. The limit of quantitation was 1.1 μg/ml. 
 
2.4 GC analysis 
The GC system (7890A, Agilent Technologies) consisted of an auto sampler and an 
injector. Nitrogen was used as the carrier gas and detection was conducted with a flame 
ionisation detector (FID). Two capillary columns were used for the selected solvents (Table 
2): Ultra 1® (Dimethyl polysiloxane, Agilent Technologies, J & W Scientific, USA) with 25 
m length, 0.20 mm internal diameter and 0.33 μm film thickness and an HP 5® [(5%-
Phenyl)-methyl polysiloxane, Agilent J & W GC column, USA] with a length of 30 m, 
internal diameter of 0.32 mm and a film thickness of 0.25 μm. The temperature range of both 
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columns was -60
°
C to 325
°
C. Data were recorded and analysed with Agilent Open Lab CDS 
Chemstation® software. The GC methods are given in detail in Table 2. PG and BD are polar 
short chain glycols (Li et al., 2007), and derivatisation was required to increase their peak 
detection and sensitivity. PG and BD were derivatised with 40 mmol phenylboronic acid in 
acetone (Ehlers et al., 2013; Porter and Auansakul, 1982). The sample and standard 
preparation method of PG was adapted from Santos et al. (Santos et al., 2009). The internal 
standards for PG and BD were 1, 2 butanediol in methanol (0.6 μmol/ml) (Santos et al., 2009) 
and n-octanol in acetonitrile (0.6 g/l) (Blanchet et al., 2002), respectively.  50 μl of standard 
solution or sample of either PG or BD and 50 μl of internal standard were placed in an 
Eppendorf® tube. After mixing, 50 μl of this mixture were taken in another Eppendorf® tube 
and 50 μl of derivatising agent were added and mixed immediately before injection. 
Calibration curves were constructed and samples were analysed by taking the ratios of the 
peak areas of the solvents and their respective internal standards.  The accuracy value for all 
the solvents was within the range of 100±4%. The RSD values of intra- and inter-day 
precision were less than 2.20% and 5%, respectively. 
 
2.5 Dynamic vapor sorption studies  
In order to examine the evaporation of candidate vehicles, a Dynamic Vapor Sorption 
(DVS) instrument (Surface Measurement Systems Ltd., Marlow, UK) was used. Nitrogen 
was used as a carrier gas, with a flow rate at 200 ml/min. The samples were analysed at 32
°
C 
and at 50% relative humidity (R.H.) for 48 h. 10 μl of neat solvent were applied to the sample 
pan. The pan was then stabilised for approximately 2 min. The weight of the applied solvent 
was then fixed as the initial weight (mg) and the experiment started. The software recorded 
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the readings (or weight of the sample gravimetrically) up to 48 h. The change in mass was 
calculated by the following formula 
                   
                  
                
            
Equation 1 
 
2.6 Finite dose permeation and mass balance studies  
‘Franz’-type vertical glass diffusion cells were used for the ANT permeation studies 
in human skin as reported previously (Oliveira et al., 2012a). Following informed consent 
and ethical approval (Research Ethics Committee reference 07/H1306/98), human skin was 
obtained from the abdomen of donors who had undergone surgery. The viable epidermis was 
prepared from Caucasian female abdominal full thickness skin by the heat separation method. 
(Kligman and Christophers, 1963). PBS solution was prepared by dissolving ten PBS tablets 
in 1 litre of deionised water (pH 7.30±0.10). As the experiment was conducted for 48 h, 
0.002% (w/v) sodium azide was used with the PBS solution. Degassed receptor solution was 
used as the receptor compartment. The area of diffusion area was accurately measured (0.8-
1.1 cm
2
). The surface temperature was confirmed to be 32±0.5
°
C (TM-22 Digitron digital 
thermometer, RS Components, Corby, UK).  A 10 µl aliquot of the saturated drug solution 
was applied in the donor compartment and spread carefully to cover the exposed surface. 200 
µl of receptor solution were withdrawn at different time intervals up to 48 h and the same 
amount of fresh temperature equilibrated receptor solution was added to replace the sample. 
At the end of the study, ANT and solvents were analysed by HPLC and GC, respectively. 
After the 48 h permeation study, the receptor medium was removed completely. The 
mass balance study was conducted and validated. The skin surface was washed twice with 1 
ml of methanol and three times with 1 ml of methanol-water (50:50) mixture. The skin was 
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removed from the Franz cell and placed in an Eppendorf® tube with 1 ml of methanol. All 
the tubes were placed in a rotor (rotating at 40 rpm) in a temperature-controlled oven 
(32±0.5
°
C) for 3 h. After extraction was completed, the tube was centrifuged at 13,000 rpm at 
32
°
C for 15 min. Aliquots were taken from the supernatant portion and analysed by HPLC 
and GC in order to quantify the amounts of ANT and respective solvents on the surface of the 
skin and inside the skin.  
 
2.7. Statistical analysis 
Data analysis was conducted with MS Excel® 2007, and the results were presented as 
mean±SD (standard deviation). IBM SPSS Statistics software (version 22.0) was used for 
statistical evaluation. The Shapiro-Wilk test was used to check the normality of the results. If 
the p value calculated from the test was greater than 0.05, the data were assumed to be 
normally distributed (parametric). One way analysis of variance (ANOVA) was done as a 
parametric test. Multiple comparisons between each individual group were performed by the 
post hoc Tukey test. For non-parametric data, Kruskal-Wallis one way ANOVA followed by 
multiple comparisons between groups was performed. Equal variance was assumed in all 
cases. p<0.05 was considered as the statistical significant difference. 
 
 
3. Results and discussion 
3.1 Log P, solubility parameter, solubility and stability studies  
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The physicochemical properties of ANT are shown in Table 2. ANT is a yellow 
powder with a relatively low molecular weight (315.32 Da). The  log P was determined to be 
1.15±0.83 and the reported melting point is 188-194
°
C (Leimgruber et al., 1965a). The 
calculated physicochemical parameters of the solvents are listed in Table 2. The first three 
solvents were selected primarily because of the proximity of their solubility parameters to 
that of ANT [15.35 (cal/cm
3
)
1/2
]. PG, BD and DiPG are low molecular weight hydrophilic 
solvents; TC is also a hydrophilic solvent with a solubility parameter close to that proposed 
for skin,  10 (cal/cm
3
)
1/2
 (Liron and Cohen, 1984). PGMC, PGML and IPM are hydrophobic 
solvents with solubility parameters that are also similar to that for human skin, and predicted 
log P values are 2.5, 4.17 and 5.86, respectively. IPM is a well-known skin penetration 
enhancer used in topical and cosmetic products (Lane, 2013). PGML is used in transdermal 
and cosmetic products (Fenton and Rowe, 2013c). PGMC has not been investigated as a 
penetration enhancer in human and porcine skin models to date. 
The solubilities for ANT in the various vehicles are shown in Table 4, with the 
highest values observed for PG followed by BD, DiPG and TC. The solubility of ANT 
ranged from 1 - 10 mg/ml in PGML, PGMC and water, and the lowest value was observed in 
IPM. It has previously been hypothesised that the lower the solubility parameter difference 
between a solute and solvent,  the higher the solubility of the solute in that solvent (Florence 
and Attwood, 2006). This appears to be the case in the present work with PG, BD and DiPG; 
PG and BD had the closest solubility parameter to ANT and therefore, the solubilities of 
ANT in these solvents were higher compared with the other solvents. As the difference 
between solvent and solute solubility parameter values increases, solubility decreases. PGMC 
and PGML have similar solubility parameter values, (Table 1), and the solubility of ANT in 
these solvents was ~5.6 mg/ml. ANT solubility was lowest in IPM and water, because of the 
high difference in solubility parameter values; the solubility parameter of water is 22.97 
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(cal/cm
3
)
1/2
. After 48 h stability studies at 32°C, the recovery of ANT in all solvents was 
>89%, with the exception of TC where ~70% ANT was recovered; ANT also demonstrated 
instability in PBS (data not shown).  
 
3.2 Solvent evaporation studies 
The results for the DVS studies of the candidate vehicles are shown in Figure 1. There 
was complete evaporation of TC and PG by 16 and 37 h, respectively. For BD, 70.3% of the 
applied mass was recovered at 48 h. Only 13% of the applied DiPG evaporated during the 
experiment. More than 94% of the applied weights of PGMC, PGML and IPM were 
recovered at the end of the experiment. PG, TC, BD and DiPG also absorbed water at early 
time points.  The value for equilibrium vapour pressure is indicative of the evaporation rate of 
a vehicle or liquid, and a liquid with a high vapour pressure is considered to be volatile 
(Sinco and Singh, 2011).  The vapour pressure of TC is higher than PG and BD (Table 3), 
consistent with the faster evaporation of TC (100% evaporation at 16 h) compared with PG 
and BD. Similarly, DiPG showed comparatively low volatility because of the lower vapour 
pressure value reported for this solvent (Table 3). The vapour pressure of PGMC and PGML 
is not reported in the literature, and the vapour pressure of IPM is very low - 9.35x10
-5
 mm 
Hg (Daubert and Danner, 1989); the DVS data confirm that these solvents are not volatile 
(Figure 1).  
 
3.3 Permeation and mass balance studies - ANT 
Finite dose permeation studies of ANT were performed using PG, BD, DiPG, TC, 
PGMC, PGML and IPM. A dose equivalent to 10 μl (8.5 - 11.2 mg) of vehicle was applied 
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on the surface of the skin. Permeation of ANT was only observed for PG, TC and PGML; 
permeation profiles are shown in Figures 2a and 2b. Preciptiation of ANT was also evident in 
the donor chamber for both PG and TC during the course of the permeation study. Figure 2a 
shows that, at 48 h, the highest amount of ANT permeated from TC (17.6 μg/cm2) followed 
by PG (12.5 μg/cm2) and PGML (8.5 μg/cm2). The values were not significantly different 
from each other (p>0.05). A curvilinear permeation profile of ANT in TC is also evident in 
Figure 2a. Permeation of ANT in PG and PGML was not detected until 5 and 8 h, 
respectively with similar permeation profiles up to 32 h. As a dose equivalent to 10 μl of a 
saturated solution of ANT in the different vehicles was applied, the percentage ANT 
permeation as a function of time is shown in Figure 2b. Although the cumulative amount of 
ANT that permeated was the lowest for PGML, the percentage permeation at 48 h was 
highest (13.1%) for this vehicle compared with the PG (0.6%) and TC (8.0%). The ability of 
PGML to act as a skin penetration enhancer has been reported previously (Hirata et al., 2013; 
Mohammed et al., 2014; Parisi et al., 2016).  It has been suggested that the presence of 
unesterified lauric acid in PGML may contribute to increased membrane permeation. The 
percentage ANT permeation at 48 h for PG is significantly lower compared with TC and 
PGML (p<0.05).  
The results for mass balance studies and permeation of ANT are shown in Table 5. 
ANT was retained inside the skin in high quantities for PG, PGMC and TC and the amounts 
were not significantly different (p>0.05). For PGML and BD, amounts of ANT recovered 
were 2.6 and 2.0 μg/cm2 respectively; application in DiPG and IPM resulted in 1.5 μg/cm2 of 
ANT retention in the skin. No significant differences were evident in the amounts of ANT 
extracted from the skin for TC, BD, DiPG, PGMC, PGML and IPM (p>0.05). Most of the 
applied dose of ANT was recovered from the donor compartment. Total amounts for ANT 
permeation and retention in skin were highest for PG and TC (38 and 27 μg/cm2, 
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respectively, p>0.05) and the value for PG is significantly higher than for the other solvents 
(p<0.05). Comparatively lower permeation and retention was evident for PGMC and PGML 
(~11 μg/cm2) compared with PG; the corresponding values for the remaining solvents were > 
6 μg/cm2.  ANT in IPM could not be quantified from the surface washings because of the low 
ANT solubility in IPM. The value for percentage skin retention of ANT for the IPM vehicle 
was relatively high (59.2%) as the applied dose of ANT was low and significantly higher than 
for the other solvents (p<0.05). Despite high retention of ANT inside the skin for PG (Table 
5), the percentage retention was very low (1.3%) because of the comparatively high dose 
applied. The second highest retention was obtained for ANT in PGMC (17.50%). The 
percentage retention of ANT for PGMC (17.5%) was significantly higher compared with PG, 
BD, TC, DiPG, water and PGML. TC and PGML showed similar values for percentage ANT 
retained in skin (p>0.05), namely 4.43 and 4.01%, respectively; BD and DiPG deposited 
comparable percentages of ANT (<0.3%). The total recovery after mass balance ideally 
should be 100±15% (Scientific Committee on Consumer safety, 2010). The total recovery of 
ANT for PG, TC and IPM was 82, 84 and 59%, respectively, while values for solvents where 
there is no permeation all fall within recommended recovery limits. This reflects the partial 
degradation of ANT in the receptor phase as noted above.  
 
3.4 Permeation and mass balance studies – solvents  
The hydrophobic vehicles (PGMC, PGML and IPM) were not detected in the receptor 
medium. The permeation profiles of the hydrophilic vehicles are shown in Figure 3. TC 
permeated through the skin in significantly higher quantities compared with the other 
solvents (p<0.05). The permeation of TC reached a plateau at 19 h (53.4%); at 48 h, a total of 
56.8% of the applied amount had permeated. The second most permeable vehicle was PG, 
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with a significantly higher percentage permeation at 48 h compared with BD and DiPG 
(p<0.05).  After 27 h, the permeation of PG appeared to plateau and at 48 h, 21.9% of the 
applied dose had permeated. Thus, at the end of the permeation study, PG permeation was 
almost 2.5-fold lower than TC (p<0.05). The permeation profiles of BD and DiPG across 
human skin were similar and final amounts permeated were 10.3% and 8.0%, respectively.  
The mass balance results for vehicles after 48 h permeation studies are shown in 
Figure 4. The percentages of PG and BD recovered from the surface of the skin by washing 
were 6.9% and 42.4% respectively. No TC was recovered from the skin surface, and this may 
reflect the comparatively more volatile nature of TC compared with PG and BD (Figure 1).  
Higher quantities of DIPG, PGMC, PGML and IPM (98.9, 96.6, 95.9 and 65.7% 
respectively) were obtained from washing the skin surface after the permeation studies 
compared with PG and BD. The total recovery values of PG and BD were also lower than 
DiPG, PGMC, PGML and IPM, and this may reflect evaporation of the glycol vehicles. The 
values for skin retention of IPM, TC and PGMC (11.3, 8.5 and 7.5%, respectively) are 
significantly higher than all other vehicles (p<0.05), but not significantly different from each 
other (p>0.05). Corresponding skin retention values for PGML, PG, BD and DiPG were 4.2, 
2.1, 1.0 and 2.1%, respectively. Significantly higher amounts of TC permeation and retention 
are evident (65.3%) compared with the other vehicles (p<0.05). The corresponding value for 
PG is 24.0%, also significantly higher than the other solvents (p<0.05). Total amounts of 
permeation and retention for BD, DiPG and IPM were ~10-11% of the applied amounts.  
Comparing the permeation profiles of ANT (Figures 2a and 2b) with that for TC, 
Figure 3), 10% of TC had permeated at 5 h, but  ~1% of ANT had permeated by this time 
point. After 19 h, the TC profile appears to level off, and ANT permeation also shows a 
plateau. This suggests that the rapid permeation and clearance of TC into the receptor 
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compartment may result in a deposition of ANT in the skin and no further permeation of 
ANT in the absence of TC.  In contrast, PG permeates more slowly and to a lower extent than 
TC (Figure 3), but continuous permeation is evident over 48 h as is the case for ANT. PGML 
was not detected in the receptor phase, but it is the only hydrophobic vehicle to promote skin 
permeation of ANT, presumably by maintaining the drug in solution in skin over the 
timeframe of the permeation study.  
For the hydrophilic vehicles, TC permeated through human skin to the greatest extent, 
and more TC was also retained in the skin compared with PG, BG and DiPG. The solubility 
parameter for TC is similar to the value proposed for skin, and this may contribute to the 
higher skin uptake and permeation of this vehicle. TC has previously been reported to 
increase the permeation and retention of various model drugs across the skin (Harrison et al., 
1996; Chadha et al., 2011; Oliveira et al., 2012b).  High TC skin uptake was also correlated 
with high uptake of methyl paraben following in vitro permeation studies in human skin;  
higher solvent sorption allows the active to partition more favourably into the skin (Oliveira 
et al., 2012b). A recent short-angle X-ray scattering (SAXS) study by Moghadam et al.  
showed increased disorder in SC treated for 24 h with TC (Moghadam et al., 2013). 
However, the amount of TC actually applied to the tissue was not reported, and the 
experiment may reflect the effects of saturation of the membrane with the solvent rather than 
finite dose conditions.  
PG is used as a solvent and penetration enhancer in many pharmaceutical and 
cosmetic products and its effects on the stratum corneum have been extensively reviewed 
(Roussel et al., 2015).. Fasano et al. investigated the steady state flux of neat PG in an infinite 
dose study in human skin. These authors estimated that application of a finite dose of PG (10 
μL/cm2) on the skin would result in ~23% dermal absorption at 24 h (Fasano et al., 2011). 
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However, in the present work, 13% of PG had permeated by 24 h and ~22% of the applied 
dose of PG had permeated at 48 h (Figure 3).  The mechanism of penetration enhancement by 
PG is still not clear but it has been suggested that PG solvates α-keratin and occupies 
hydrogen-bonding sites of the SC (Roussel et al., 2015; Lane, 2013). Bouwstra and co-
workers (Bouwstra et al., 1991) suggested that PG intercalates with the SC lipid head groups, 
thus causing a lateral swelling of the lipid alkyl chains by an increase in interfacial area. The 
recent SAXS study reported by Moghadam et al. (2013) showed that PG did not influence the 
long or short lamellar spacing of the SC. In general, it is considered that PG may act by 
increasing the partition or solubility of a drug in the SC (Lane, 2013).  Pudney et al. (2007) 
and Mohammed et al. (2014) used Confocal Raman spectroscopy to investigate the in vivo 
distribution of PG in humans and noted that the depth of penetration of PG correlated well 
with the active that was applied in the PG vehicle to the forearm. This is consistent with the 
results observed for the in vitro studies in Figures 2 and 3. Low permeation values of BD and 
DiPG (~8 to 10%) were observed (Figure 3) with no quantifiable permeation of ANT in 
either of the vehicles. BD permeated to a slightly higher extent (~10%) than DiPG (~8%), 
whereas as shown in Figure 4 the amount of DiPG deposited inside the skin almost 2-fold 
higher than for BD (~2 and 1%, respectively). However, ANT deposition inside skin was not 
significantly different for BD and DiPG. Fasano et al. (2011) conducted infinite dose 
permeation studies with DiPG using human abdominal skin. The flux of DiPG across the skin 
was almost 3-fold lower than for PG; interestingly, the cumulative flux of DiPG in the 
present finite dose study is also 3-fold lower than the value for PG. The authors also 
estimated that if a finite dose is applied (10 μl/cm2), DiPG might permeate up to 9% at the 
end of 24 h. Figure 3 shows that the percentage of DiPG permeation was 2.6% at 24 h and 
8% at 48 h.   
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The vehicle-skin retention data showed that IPM and PGMC were retained inside the 
skin in higher quantities than PGML, and skin retention of these vehicles follows the same 
trend as skin retention of ANT, namely IPM>PGMC>PGML. Greater partitioning and higher 
skin retention was demonstrated for IPM compared with alkanols by Goldberg-Cettina et al. 
(1995). Liu et al. (2009) investigated the effects of IPM on estradiol skin permeation and 
noted that IPM uptake could be correlated with drug diffusivity in skin. The authors also 
demonstrated swelling of the SC in the presence of IPM. Oliveira et al. (2012b) also reported 
a direct dependence of methyl paraben uptake into SC on IPM sorption into the membrane, 
consistent with the present work.  
4. Conclusions 
The skin permeation and retention of a model PBD compound, ANT, has been 
investigated for a range of neat solvents. TC and PGML delivered higher amounts of ANT 
through the skin compared with the other vehicles. The delivery of ANT clearly “tracked” the 
skin penetration of TC and, to a lesser extent, PG, emphasising the critical role of the vehicle 
in the skin delivery of the active. Skin penetration of ANT also mirrored the evaporation of 
PG and TC. In the management of AK or skin cancer, the active needs to target the outer 
layers of the skin and thus the lack of permeation observed for certain vehicles does not 
necessarily rule them out in future formulation development.  The stability of ANT warrants 
further investigation, given some of the low recovery values observed. More complex binary 
and ternary solvent systems may promote enhanced skin permeation of ANT via synergistic 
effects, and these will be the subject of a future publication.  
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Table 1. GC analytical methods for solvents 
 olvents→ PG BD TC DiPG PGMC PGML IPM 
Column HP 5 HP 5 Ultra 1 Ultra 1 Ultra 1 HP 5 HP 5 
Injection volume 
(μl) 
1 1 2 2 2 1 2 
Split ratio 25 25 50 5 50 25 40 
Flow rate (ml/min) 2 1.5 2 0.8 2 1.2 1 
Inlet temperature 
(
°
C) 
250 240 300 300 300 360 250 
Detector 
temperature (
°
C) 
300 280 250 250 250 300 300 
Run time (min) 8 10 11 11 12.78 8 12 
O
v
en
 c
o
n
d
it
io
n
 
Initial 
temperature 
(
°
C) 
100 120 120 110 100 100 125 
Hold time at 
initial temp 
(min) 
2 2 1 0 1 0 0 
Final 
temperature 
(
°
C) 
280 240 225 190 225 280 185 
Ramp to 
final 
temperature 
(
°
C/min) 
30 20 11.6 8 11.6 30 30 
Hold time in 
final temp 
(min) 
0 2 1 1 1 2 10 
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Table 2. Physicochemical properties of ANT. 
Chemical structure 
 
Molecular formula : C16H17N3O4 
Molecular weight : 315.32 Da 
Log P : 1.15±0.83 
Melting point : 188-194
°
C (Leimgruber et al., 1965a) 
Solubility parameter : 15.35 (cal/cm
3
)
1/2
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Table 3. Physicochemical parameters of candidate solvents 
Solvent Chemical structure 
Molecula
r weight 
(Da) 
Log 
P 
Vapour 
pressure 
(mm of Hg) 
Solubility 
parameter 
(cal/cm
3
)
1/
2
 
PG 
 
76.09 
-
0.47 
0.07 at 20°C 
(Ladyzhynsky
, 2013) 
14.07 
BD 
 
90.14 
-
0.37 
0.06 at 20°C 
(Fenton and 
Rowe, 2013a) 
14.09 
TC 
 
134.17 
-
0.25 
0.12 at 20°C 
(Subra, 2013) 
10.62 
DiPG 
 
134.17 
-
0.31 
0.02 at 25°C 
(Fenton and 
Rowe, 2013b) 
12.19 
      
PGMC 
 
202.29  2.5 - 9.89 
PGML 
 
258.40 
(Fenton and 
Rowe, 
2013c) 
4.17 - 9.44 
IPM 
 
270.45 
(Taylor, 
2013) 
5.86 
9.35E-05 at 
25°C (Daubert 
and Danner, 
1989)  
8.21 
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Table 4. Solubility of ANT in candidate vehicles at 32±0.5
°
C (n=3, mean±SD). 
Vehicle Solubility (mg/ml) 
PG 172.93±28.39 
BD 74.60±8.11 
DiPG 67.26±14.22 
TC 23.99±5.16 
PGMC 5.60±0.90 
PGML 5.65±0.70 
IPM 0.24±0.04 
Water 2.18±0.16 
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Table 5. Percentage of ANT recovered from skin surface, inside the skin and permeation 
into? (mean±SD, n≥3) 
 
Percentage (%) of applied dose   
Solvent From the surface Inside the skin Permeation  
PG 80.1±3.2 1.3±0.7 0.6±0.1 
TC 71.6±25.0 4.4±1.6 8.0±2.9 
BD 102.3±9.6 0.3±0.1 0 
DiPG 98.45±15.3 0.2±0.0 0 
PGMC 73.8±16.8 17.5±8.2 0 
PGML 75.1±21.4 4.0±1.0 13.1±0.4 
IPM 0 59.2±7.1 0 
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Figure 1. Percentage of the applied weight of solvents remaining as measured with Dynamic 
Vapor Sorption,over 48 h at 32±1
°
C and 50±1.5% RH (n=3, mean±SD) 
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Figure 2. (a) Cumulative amount of ANT permeated (μg/cm2) and (b) percentage of the 
applied dose of ANT permeated as a function of time (h) from single solvents across human 
skin (n≥3, mean± D).(†) indicates p>0.05. 
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Figure 3. Percentage permeation of PG, BD, TC and DiPG across human skin vs. time (n≥3, 
mean± D). (†) indicates no significant differences (p>0.05). 
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Figure 4: Percentages of solvents recovered from skin surface, inside the skin and permeated 
after 48 h permeation in human skin (n≥3, mean± D).   
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